Conformis, Inc. (NASDAQ:CFMS) announced today financial results for
the second quarter ended June 30, 2020.
Second Quarter 2020 Summary
- Total revenue of $19.5 million, a decrease of 1% year-over-year
on a reported and constant currency basis.
- Product revenue of $9.7 million, a decrease of 50%
year-over-year on a reported and constant currency
basis.• U.S. product revenue of $8.3 million, a decrease of
52% year-over-year.• Rest of World product revenue of $1.4
million, a decrease of 34% year-over-year on a reported basis and
33% on a constant currency basis.
- Royalty revenue of $9.7 million, including $9.6 million from
the previously disclosed settlement and license agreement with
Zimmer Biomet.
- Gross margin of 57%, an increase of 750 basis points
year-over-year, including the impact from the Zimmer Biomet
settlement and license agreement.
- Total operating expenses decreased 14% year-over-year.
"We are excited to announce today the launch of a new program
aimed at developing a knee replacement offering targeted at
hospital outpatient and ambulatory surgery centers (ASCs),” said
Mark Augusti, President and Chief Executive Officer. “As we have
stated previously, during the COVID-19 pandemic, we have maintained
our focus on new product development and our commitment to revenue
growth through portfolio expansion. Achieving hip growth of 12%
during arguably one of the toughest commercial environments ever in
orthopedics demonstrates the importance of new product
vitality."
Conformis will provide more information about planned changes to
its product portfolio and longer-term financial targets during the
webcast scheduled for today at 4:30 p.m. Eastern Time.
|
Three months
ended June 30, |
Increase/(decrease) |
($, in
thousands) |
2020 |
2019 |
$ Change |
% Change |
% Change |
|
|
|
|
(as reported) |
(constant currency) |
United States |
$ |
8,331 |
|
$ |
17,194 |
|
$ |
(8,863 |
) |
(52 |
)% |
(52 |
)% |
Rest of world |
1,412 |
|
2,143 |
|
(731 |
) |
(34 |
)% |
(33 |
)% |
Product
revenue |
9,743 |
|
19,337 |
|
(9,594 |
) |
(50 |
)% |
(50 |
)% |
Royalty
revenue |
9,725 |
|
256 |
|
9,469 |
|
3,699 |
% |
3,699 |
% |
Total
revenue |
$ |
19,468 |
|
$ |
19,593 |
|
$ |
(125 |
) |
(1 |
)% |
(1 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second Quarter 2020 Financial Results
Total revenue for the three-month period ended June 30,
2020 decreased $0.1 million to $19.5 million, or 1% year-over-year
on a reported and constant currency basis. Total revenue in each of
the second quarter of 2020 and 2019 includes royalty and licensing
revenue of $9.7 million and $0.3 million, respectively, related to
patent license agreements. The increase in royalty revenue in
the second quarter of 2020 compared to the same quarter in the
prior year is primarily due to the patent license settlement of
$9.6 million due from Zimmer Biomet.
Product revenue decreased $9.6 million to $9.7 million, or 50%
year-over-year on a reported and constant currency basis. U.S.
product revenue decreased $8.9 million to $8.3 million, or 52%
year-over-year, and Rest of World product revenue decreased $0.7
million to $1.4 million, or 34% year-over-year on a reported basis
and 33% on a constant currency basis. Conformis Hip System sales in
the second quarter of 2020 were up 12.0% to $0.6 million, which
were all in the United States.
Total gross profit increased $1.4 million to $11.0 million, or
57% of revenue, in the second quarter of 2020, compared to $9.6
million, or 49% of revenue, in the second quarter of
2019. This 750 basis point increase in gross margin
year-over-year was driven primarily by the $9.6 million Zimmer
Biomet patent license settlement.
Total operating expenses decreased $2.2 million to $13.3
million, or 14% year-over-year, primarily due to lower variable
expenses as a result of the decline in revenue.
Net loss was $2.1 million, or $0.03 per basic and diluted share,
in the second quarter of 2020, compared to a net loss of $6.8
million, or $0.11 per basic and diluted share, in the same period
last year. Net loss in the second quarter of 2020 included foreign
currency exchange income of $0.7 million, compared to foreign
currency exchange income of $0.4 million in the same period last
year. Net loss per basic and diluted share calculations
assume weighted average basic and diluted shares outstanding of
68.2 million for the second quarter of 2020, compared to 63.3
million for the same period last year.
Cash and cash equivalents totaled $18.2 million as of
June 30, 2020, compared to $26.4 million as of
December 31, 2019.
Note on Non-GAAP Financial
Measures
In addition to disclosing financial measures prepared in
accordance with U.S. generally accepted accounting principles
(GAAP), the Company provides certain information regarding the
Company's financial results or projected financial results on a
non-GAAP "constant currency basis." This information estimates the
impact of changes in foreign currency rates on the translation of
the Company's current or projected future period financial results
as compared to the applicable comparable period. This impact is
derived by taking the adjusted current or projected local currency
results and translating them into U.S. dollars based upon the
foreign currency exchange rates for the applicable comparable
period. It does not include any other effect of changes in foreign
currency rates on the Company's results or business. Non-GAAP
information is not a substitute for, and is not superior to,
information presented on a GAAP basis. Company management uses
these non-GAAP measures internally to measure operational
performance.
Webcast
As previously announced, Conformis will conduct a webcast today
at 4:30 p.m. Eastern Time. Management will discuss financial
results and strategic matters. The webcast will be live at
https://edge.media-server.com/mmc/p/phu3zyop.
The online archive of the webcast will be available on the
Company's website for 30 days.
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit Image-to-Implant technology platform to develop,
manufacture and sell joint replacement implants and instruments
that are individually sized and shaped, which we refer to as
personalized, individualized, or sometimes as customized, to fit
each patient's unique anatomy. Conformis offers a broad line
of sterile, personalized knee and hip implants and single-use
instruments delivered to hospitals and ambulatory surgical
centers. In clinical studies, Conformis iTotal CR knee
replacement system demonstrated superior clinical outcomes,
including better function and greater patient satisfaction,
compared to traditional, off-the-shelf implants. Conformis
owns or exclusively in-licenses issued patents and pending patent
applications that cover personalized implants and patient-specific
instrumentation for all major joints.
For more information, visit www.conformis.com. To receive
future releases in e-mail alerts, sign up at ir.conformis.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, including statements about the impact of the
novel coronavirus (COVID-19) pandemic and the actions we are taking
and planning in response, our planned launch of a new program aimed
at developing a knee replacement offering targeted at hospital
outpatient and ambulatory surgery centers, the anticipated timing
of our product launches, whether or when restrictions on elective
surgeries will be relaxed and demand for procedures will increase
and our financial position and results, total revenue, product
revenue, gross margin, operations and growth, as well as other
statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "project," "should,"
"target," "will," or "would" and similar expressions, constitute
forward-looking statements within the meaning of the safe harbor
provisions of The Private Securities Litigation Reform Act of 1995.
We may not actually achieve the forecasts disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual financial results could
differ materially from the projections disclosed in the
forward-looking statements we make as a result of a variety of
risks and uncertainties, including risks related to the novel
coronavirus pandemic and the response to the pandemic; whether our
cash resources will be sufficient to fund our continuing operations
for the periods anticipated; risks related to our estimates and
expectations regarding our revenue, gross margin, expenses, revenue
growth and other results of operations, and the other risks and
uncertainties described in the "Risk Factors" sections of our
public filings with the U.S. Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent our views as of the date hereof. We anticipate
that subsequent events and developments may cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date hereof.
CONFORMIS,
INC. AND SUBSIDIARIES |
Consolidated
Statements of Operations |
(unaudited) |
(in
thousands, except share and per share data) |
|
|
Three Months Ended June 30, |
|
2020 |
|
2019 |
|
|
|
|
Revenue |
|
|
|
Product |
$ |
9,743 |
|
|
$ |
19,337 |
|
Royalty and licensing |
9,725 |
|
|
256 |
|
Total revenue |
19,468 |
|
|
19,593 |
|
Cost of revenue |
8,450 |
|
|
9,971 |
|
Gross profit |
11,018 |
|
|
9,622 |
|
|
|
|
|
Operating expenses |
|
|
|
Sales and marketing |
4,102 |
|
|
6,897 |
|
Research and development |
2,738 |
|
|
3,328 |
|
General and administrative |
6,474 |
|
|
5,289 |
|
Total operating expenses |
13,314 |
|
|
15,514 |
|
Loss from operations |
(2,296 |
) |
|
(5,892 |
) |
|
|
|
|
Other income and expenses |
|
|
|
Interest income |
23 |
|
|
91 |
|
Interest expense |
(584 |
) |
|
(1,337 |
) |
Foreign currency exchange transaction income |
694 |
|
|
398 |
|
Total other income (expenses) |
133 |
|
|
(848 |
) |
Loss before income taxes |
(2,163 |
) |
|
(6,740 |
) |
Income tax provision |
(28 |
) |
|
23 |
|
|
|
|
|
Net loss |
$ |
(2,135 |
) |
|
$ |
(6,763 |
) |
|
|
|
|
Net loss per share |
|
|
|
Basic and diluted |
$ |
(0.03 |
) |
|
$ |
(0.11 |
) |
Weighted average common shares
outstanding |
|
|
|
Basic and diluted |
68,187,128 |
|
|
63,333,737 |
|
|
|
|
|
|
|
CONFORMIS,
INC. AND SUBSIDIARIES |
Consolidated
Balance Sheets |
(in
thousands, except share and per share data) |
|
|
|
|
|
June 30, 2020 |
|
December 31, 2019 |
Assets |
(unaudited) |
|
|
Current Assets |
|
|
|
Cash and cash equivalents |
$ |
18,168 |
|
|
$ |
26,394 |
|
Accounts receivable, net |
8,186 |
|
|
11,066 |
|
Royalty and licensing receivable |
6,197 |
|
|
165 |
|
Inventories, net |
13,181 |
|
|
12,074 |
|
Prepaid expenses and other current assets |
2,223 |
|
|
2,815 |
|
Total current assets |
47,955 |
|
|
52,514 |
|
Property and equipment, net |
13,755 |
|
|
13,356 |
|
Operating lease right-of-use assets |
5,274 |
|
|
5,853 |
|
Other Assets |
|
|
|
Restricted cash |
462 |
|
|
462 |
|
Other long-term assets |
189 |
|
|
211 |
|
Total assets |
$ |
67,635 |
|
|
$ |
72,396 |
|
|
|
|
|
Liabilities and stockholder's
equity |
|
|
|
Current liabilities |
|
|
|
Accounts payable |
$ |
6,443 |
|
|
$ |
6,920 |
|
Accrued expenses |
7,014 |
|
|
7,135 |
|
Operating lease liabilities |
1,489 |
|
|
1,469 |
|
Advance on research and development |
3,149 |
|
|
2,331 |
|
Contract liability |
12,000 |
|
|
— |
|
Total current liabilities |
30,095 |
|
|
17,855 |
|
Other long-term liabilities |
— |
|
|
1,500 |
|
Contract liability |
— |
|
|
12,000 |
|
Long-term debt, less debt issuance costs |
24,664 |
|
|
19,623 |
|
Operating lease liabilities |
4,433 |
|
|
5,071 |
|
Total liabilities |
59,192 |
|
|
56,049 |
|
Commitments and
contingencies |
|
|
|
Stockholders' equity |
|
|
|
Preferred stock, $0.00001 par value: |
|
|
|
Authorized: 5,000,000 shares authorized at June 30, 2020 and
December 31, 2019; no shares issued and outstanding as of June 30,
2020 and December 31, 2019 |
— |
|
|
— |
|
Common stock, $0.00001 par value: |
|
|
|
Authorized: 200,000,000 shares authorized at June 30, 2020 and
December 31, 2019; 76,103,605 and 70,427,400 shares issued and
outstanding at June 30, 2020 and December 31, 2019,
respectively |
1 |
|
|
1 |
|
Additional paid-in
capital |
524,991 |
|
|
521,356 |
|
Accumulated deficit |
(515,633 |
) |
|
(504,145 |
) |
Accumulated other
comprehensive loss |
(916 |
) |
|
(865 |
) |
Total stockholders' equity |
8,443 |
|
|
16,347 |
|
Total liabilities and stockholders' equity |
$ |
67,635 |
|
|
$ |
72,396 |
|
|
|
|
|
|
|
|
|
CONTACT:
Investor contact
ir@conformis.com
(781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024